Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia

NCT00686218 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

DRUG: imatinib mesylate
DRUG: panobinostat
GENETIC: polymerase chain reaction
GENETIC: protein expression analysis
GENETIC: western blotting
OTHER: flow cytometry
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

City of Hope Medical Center

Collaborators

[object Object]